Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch
Novartis completed its filing to the
FDA for approval of the radioligand therapy manufacturing facility at Millburn,
NJ for commercial production of Pluvicto (Lutetium-177 vipivotide tetraxetan,
formerly referred to as 177Lu-PSMA-617) for the treatment of
patients with PSMA (Prostate specific membrane antigen) positive castration
resistant prostate cancer patients. With FDA approval, Millburn could begin
supplying Pluvicto by this summer, expanding its current manufacturing
capacity.
To read more please visit:
Novartis
completes FDA filing for approval of Millburn facility to support Pluvicto®
launch
Source: Novartis